International Clinical Trial: Randomized Controlled Trial of Camrelizumab Combined with EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119577) titled 'Randomized Controlled Trial of Camrelizumab Combined with EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma' on Feb. 28.

Study Type: Interventional study

Study Design: Parallel

Primary Sponsor: Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

Condition: Pathologically diagnosed squamous cell carcinoma, primary head and neck tumor of clinical stage III-IVb (AJCC 8th edition) (excluding nasopharyngeal cancer).

Intervention: Control group:Camrelizumab + Chemotherapy

Recruitment Status: Not Recruitin...